New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
|Videos|July 17, 2014
Memory T Cell Responses Following Anti-CTLA-4 Antibody Treatment
Author(s)Lawrence Fong, MD
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
Advertisement
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses research to examine the immunobiology and biomarkers associated with improved clinical outcomes seen during treatment with an anti-CTLA-4 antibody.
Clinical Pearls:
- Because these treatments change the T cells that are circulating in patients, it may take time for patients to develop T cells that can see the cancer.
- Researchers found that patients who have high frequencies of T cells tend have the longest survival when receiving treatment with an anti-CTLA-4 antibody.
- By discovering the benefit of having this pre-existing response, physicians can make better choices when treating patients.
Advertisement
Related to this article
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5